3[3]Esmon CT. Introduction: are natural anticoagulation candidates for modulating the inflarnrnatory response to endotoxin? Blood, 2000, 95:1113.
4[4]Scherer RU, Spangenberg P. P~lant activity in patients withisolated head trauma. Crit Care Med, 1998,26:149.
5[5]Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med, 1999,341:586.
6[6]Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.Semin Thromb Hemost, 1998,24:33.
7[7]Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med, 2000, 28(Suppl): S77.
8[8]Dickneite G. Antithrombin Ⅲ in animal models of sepsis and organ failure. Semin Thromb Hemost, 1998,24: 61.
9[9]Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl JMed, 2001,344:699.
10[10]Eisele B, Lamy M, ThijsL G, et al. Antithrombin Ⅲ in patients with severe sepsis. A randomized, double-blinded, plaeebo-controlled multicenter trial plus a meta-analysis on all randomized, double-blinded, placebo-controlled trials with Antithrombin Ⅲ in severe sepsis. Intensive Care Med, 1998,24:663.
